Psoriasis and Psoriatic Arthritis: A Strategic Analysis of the Market in the United States

Description: This report focuses on the applications of current and advanced therapeutics to the treatment of psoriasis and psoriatic arthritis, the options they present, and the progress that is being made in these fields. The major market effects of new therapeutics, with the potential of a breakthrough drug always a possibility, are expected to be seen over the next ten years. The technology trends selected in conjunction with the growing interest in psoriasis and its treatment present the most informative picture of advances in psoriasis and psoriatic arthritis therapeutics and the markets that result.

The report's market analysis includes:
- Extensive discussion of the pathology of the multiple forms of the disease
- Thorough examination of the epidemiology in the United States segmented by severity and projected to 2016
- Comprehensive analysis of the total available market and serviceable available market for psoriasis (by severity) and psoriatic arthritis through 2016
- Monthly cost per patient forecasts for psoriasis (by severity) and psoriatic arthritis through 2016

In depth company profiles of major competitors and a meticulous review of the expert conclusions and strategic implications for competitors serious about winning in the psoriasis therapeutics field round out this systematic analysis.

The analysis presented in this report is based on data from a combination of company, government, industry, institutional and private sources. It includes information from extensive literature reviews and discussions with experts in the field, including immunologists, dermatologists, rheumatologists, pathologists, research scientists, business development managers and marketing managers.

Contents: Chapter One: Executive Summary

Overview
Types
Scope and Methodology
Market Analysis
Trends and Considerations

CHAPTER Two: Pathology and Epidemiology

Overview
Tumor Necrosis Factor á
Contributing Factors
National Psoriasis Foundation Survey
Daily Life Impacts
Problems Receiving Services Due to Perception of Their Disease
Quality of Life

Pathology of Psoriasis
Types
Plaque Psoriasis
Guttate Psoriasis
Inverse Psoriasis
Pustular Psoriasis
Erythrodermic Psoriasis
Types by Location
Scalp Psoriasis
Types by Severity
Pathology of Psoriatic Arthritis
The Genetics of Psoriasis and Psoriatic Arthritis
Psoriasis and Psoriatic Arthritis Epidemiology

CHAPTER Three: Current Therapies

Topical Therapy
Anthralin
Calcipotriene
Coal Tar
Salicylic Acid
Corticosteroids (Steroids)
Vitamin A
Sunlight and Water (Climatotherapy)

Phototherapy
UV-B Therapy
PUVA

Systemic Treatments
Corticosteroids
Cyclosporine
Methotrexate
Retinoids
Aspirin and Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
Biological DMARDS
T-Cell Agents
Monoclonal TNF Antibodies
Soluble TNF Receptor Inhibitors

New Developments
Alternative Therapies
Acupuncture
Ayurvedic Medicine
Chinese Medicine
Chiropractic
Homeopathic Medicine
Naturopathic Medicine
Glucosamine and Chondroitin
Methylsulfonylmethane (MSM)
S-adenosylmethionine (SAM-e)
Magnetic Therapy

CHAPTER Four: Market Analysis

Forecasting Challenges
Market Size and Cost of Treatment
Total Available Market vs Serviceable Available Market
Competition

CHAPTER Five: Company Profiles

Amgen
Angiotech Pharmaceuticals
Biogen IDEC
Centocor, Inc.
Galderma Laboratories
Isis Pharmaceuticals, Inc.
Isotechnika, Inc.
Ligand Pharmaceuticals
Vertex Pharmaceuticals

CHAPTER Six: Conclusions and Strategic Implications
First Conclusion
Implications:
Second Conclusion
Implications:
Third Conclusion
Implications:
Fourth Conclusion
Implications:
Fifth Conclusion
Implications:
Sixth Conclusion
Implications:
Seventh Conclusion
Implications:
Eighth Conclusion
Implications:
Appendix: Company Directory

List of Exhibits

Chapter One: Executive Summary

Table 1-1: Prevalence of Psoriasis and Psoriatic Arthritis in the United States 2006-2016
Figure 1-1: Distribution of Psoriasis Cases in the United States by Severity: 2006
Table 1-2: Common Psoriasis Treatments
Table 1-3: The Total Available Market for Psoriasis and Psoriatic Arthritis Therapeutics in the United States by Severity 2006-2016
Figure 1-2: Trending in the Total Available Market (TAM) for Psoriasis and Psoriatic Arthritis Therapeutics in the United States: 2006-2016
Table 1-4: Serviceable Available Market (SAM) for Psoriasis and Psoriatic Arthritis Therapeutics in the United States by Severity 2006-2016
Figure 4-3: Trending in the Serviceable Available Market (SAM) for Psoriasis and Psoriatic Arthritis Therapeutics in the United States: 2006-2016

CHAPTER Two: Pathology and Epidemiology

Table 2-1: Types of Psoriasis and Their Characteristics
Table 2-2: Psoriasis Assessment Methods
Table 2-3: Type of Psoriatic Arthritis (PsA) and Their Characteristics
Table 2-4: Prevalence of Psoriasis and Psoriatic Arthritis in the United States by Type 2006-2016
Figure 2-1: Prevalence of Psoriasis, by Severity, in the United States 2006-2016
Figure 2-2: Prevalence of Psoriasis and Psoriatic Arthritis in the United States 2006-2016

CHAPTER Three: Current Therapies

Table 3-1: Psoriasis and Psoriatic Arthritis Therapeutics and Treatment Products
Table 3-2: The Psoriasis Treatment Ladder
Table 3-3: Steroid Potency Classes and Products
Table 3-4: Phototherapy Skin Types
Table 3-5: Phototherapy Equipment Manufacturers
Table 3-6: Comparison of Biological Therapeutics for Psoriasis and Psoriatic Arthritis
Table 3-7: Treatments in Development for Psoriasis and Psoriatic Arthritis

CHAPTER Four: Market Analysis

Table 4-1: Total Available Market (TAM) for Psoriasis (by Severity) and Psoriatic Arthritis Therapeutics in the United States: 2006-2016
Figure 4-1: Trending in the Total Available Market (TAM) for Psoriasis and Psoriatic Arthritis Therapeutics in the United States: 2006-2016
Figure 4-2: Composition of the Total Available Market (TAM) for Psoriasis and Psoriatic Arthritis Therapeutics in the United States: 2006-2016
Table 4-2: Estimated Monthly Cost per Patient for the Medicinal Treatment of Psoriasis (by Severity) and Psoriatic Arthritis in the United States 2006-2016
Table 4-3: Serviceable Available Market (SAM) for Psoriasis (by Severity) and Psoriatic Arthritis Therapeutics in the United States: 2006-2016
Figure 4-3: Trending in the Serviceable Available Market (SAM) for Psoriasis and Psoriatic Arthritis Therapeutics in the United States 2006-2016
Figure 4-4: Composition of the Serviceable Available Market (SAM) for Psoriasis and Psoriatic Arthritis Therapeutics in the United States 2006-2016
Table 4-4: Active Competitors in Ethical Pharmaceuticals for Psoriasis and Psoriatic Arthritis in the United States
Figure 4-3: Trending in Average Monthly Medicinal Treatment Costs for Psoriasis (by Severity) and Psoriatic Arthritis: 2006-2016

Ordering: Order Online - http://www.researchandmarkets.com/reports/2860746/
Order by Fax - using the form below
Order by Post - print the order form below and send to
   Research and Markets,
   Guinness Centre,
   Taylors Lane,
   Dublin 8,
   Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Psoriasis and Psoriatic Arthritis: A Strategic Analysis of the Market in the United States
Web Address: http://www.researchandmarkets.com/reports/2860746/
Office Code: SCD2AZ6F

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User</td>
<td>□</td>
<td>USD 1500</td>
</tr>
<tr>
<td>Hard Copy</td>
<td>□</td>
<td>USD 3500 + USD 57 Shipping/Handling</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide</td>
<td>□</td>
<td>USD 7000</td>
</tr>
</tbody>
</table>

* Shipping/Handling is only charged once per order.

Contact Information
Please enter all the information below in BLOCK CAPITALS

<table>
<thead>
<tr>
<th>Title:</th>
<th>Mr □ Mrs □ Dr □ Miss □ Ms □ Prof □</th>
</tr>
</thead>
<tbody>
<tr>
<td>First Name:</td>
<td>_________________________________</td>
</tr>
<tr>
<td>Email Address: *</td>
<td>_________________________________</td>
</tr>
<tr>
<td>Job Title:</td>
<td>_________________________________</td>
</tr>
<tr>
<td>Organisation:</td>
<td>_________________________________</td>
</tr>
<tr>
<td>Address:</td>
<td>_________________________________</td>
</tr>
<tr>
<td>City:</td>
<td>_________________________________</td>
</tr>
<tr>
<td>Postal / Zip Code:</td>
<td>_________________________________</td>
</tr>
<tr>
<td>Country:</td>
<td>_________________________________</td>
</tr>
<tr>
<td>Phone Number:</td>
<td>_________________________________</td>
</tr>
<tr>
<td>Fax Number:</td>
<td>_________________________________</td>
</tr>
</tbody>
</table>

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:

Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code:  

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:

(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World